Quality
At Boehringer Ingelheim, Quality is deeply embedded into the lifecycle of the product: from Research and development to the delivery to our patients.
Search
Genomic Lens Linking Worlds in DNA
Adding a new dimension to drug discovery with the help of data science and DNA
clinical-collaboration-with-Amgen
Collaboration to study Boehringer Ingelheim’s SOS1::pan-KRAS Inhibitor in combination with Amgen’s KRASG12C Inhibitor
Stroke Prevention in AF
Stroke Prevention in AF
BI_PharmAccess_launch_digital_healthcare_program
Boehringer Ingelheim and PharmAccess launch a new mobile support program „Tiba Yako“ to empower patients to become more aware, access care and take charge of their disease management
2021 ABCD Young Scientist Award feline health
Young veterinary researchers Julia Klaus and Dr Yasmin Parr receive award for their work into feline SARS-CoV-2 infections and feline leukaemia virus.
EMPRISE-Study
EMPRISE-Study
reduced-heart-failure-treatment-approval-europe
European approval for treatment of adults with heart failure with reduced ejection fraction
Life forward - Boehringer Ingelheim company brand
Life forward - Boehringer Ingelheim unveils its evolved company brand
Investigational treatment slowed lung function decline in IPF
Investigational treatment slowed lung function decline in IPF
Our culture
Our culture reflects who we are and is reflected in Our FOCUS and strong belief in Diversity, Equity and Inclusion as well as Sustainable Development.
LastMile initiative to address barriers in animal healthcare
The ‘LastMile’ initiative addresses major barriers in animal healthcare sector in Sub-Saharan African
Expectations towards our business partners
We utilize an extensive network of international suppliers for procuring raw materials, intermediates, packaging materials, technical components and services to deliver our innovative medications worldwide.
Our Expectations
We expect adherence to exemplary ethical and professional conduct both within the company and from our business partners.
Boosting performance with an inclusive performance culture
Boosting performance of organizations with an inclusive performance culture
Launch VETMEDIN Solution oral solution congestive heart failure in dogs
The new VETMEDIN® Solution offers pet owners a convenient, liquid oral treatment option for those dogs that prefer a liquid
cat feline diabetes medication treatment fda approval
Boehringer Ingelheim receives FDA approval for SENVELGO®
Boehringer Ingelheim appointment to Board Managing Directors
Boehringer Ingelheim announces appointments to Board of Managing Directors
SPEVIGO (spesolimab) wins 2023 Prix Galien USA Award
SPEVIGO® (spesolimab) wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award
What everyone should know about heartworms
Heartworms are dangerous parasites that can infest pets through mosquito bites, causing serious illness. Here are key facts we all should know about heartworms.
FDA approval NexGard PLUS for dogs
Boehringer Ingelheim Receives FDA Approval for NexGard® PLUS - A Beef-Flavored Soft Chew That Protects Dogs from Internal and External Parasites
Our people
Ambition. Passion. Integrity. Commitment. Empathy. Individuality. We expect these qualities at all levels.
Over 100 billion birds vaccinated with VAXXITEK
Boehringer Ingelheim celebrates that over 100 billion birds have been vaccinated with VAXXITEK® HVT + IBD in October 2018.
Geographic Atrophy treatment to move to Phase II
Geographic Atrophy treatment BI 771716 to move to Phase II, following positive Phase I results
Heart Failure in Women
Experts discuss disparities in heart failure care and management for women